Rapid pathogen identification and antimicrobial susceptibility testing in in vitro endophthalmitis with matrix assisted laser desorption-ionization Time-of-Flight Mass Spectrometry and VITEK 2 without prior culture.

PURPOSE: Prompt clinical diagnosis and initiation of treatment are critical in the management of infectious endophthalmitis. Current methods used to identify causative agents of infectious endophthalmitis are mostly inefficient, owing to suboptimal sensitivity, length, and cost. Matrix Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) can be used to rapidly identity pathogens without a need for culture. Similarly, automated antimicrobial susceptibility test systems (AST, VITEK 2) provide accurate antimicrobial susceptibility profiles. In this proof-of-concept study, we apply these technologies for the direct identification and characterization of pathogens in vitreous samples, without culture, as an in vitro model of infectious endophthalmitis.
METHODS: Vitreous humor aspirated from freshly enucleated porcine eyes was inoculated with different inocula of Staphylococcus aureus (S. aureus) and incubated at 37°C. Vitreous endophthalmitis samples were centrifuged and pellets were directly analyzed with MALDI-TOF MS and VITEK 2 without prior culture. S. aureus colonies that were conventionally grown on culture medium were used as control samples. Time-to-identification, minimum concentration of bacteria required for identification, and accuracy of results compared to standard methods were determined.
RESULTS: MALDI-TOF MS achieved accurate pathogen identification from direct analysis of intraocular samples with confidence values of up to 99.9%. Time from sample processing to pathogen identification was <30 minutes. The minimum number of bacteria needed for positive identification was 7.889x106 colony forming units (cfu/μl). Direct analysis of intraocular samples with VITEK 2 gave AST profiles that were up to 94.4% identical to the positive control S. aureus analyzed per standard protocol.
CONCLUSION: Our findings demonstrate that the direct analysis of vitreous samples with MALDI-TOF MS and VITEK 2 without prior culture could serve as new, improved methods for rapid, accurate pathogen identification and targeted treatment design in infectious endophthalmitis. In vivo models and standardized comparisons against other microbiological methods are needed to determine the value of direct analysis of intraocular samples from infectious endophthalmitis with MALDI-TOF MS and VITEK 2.

Introduction

Infectious endophthalmitis is a serious intraocular infection that can lead to rapid irreversible visual loss despite aggressive medical and surgical management. It is caused by the replication of bacterial, mycobacterial, or fungal agents in the intraocular chambers, and can occur in the setting of surgery, intraocular injections, trauma, contiguous spread from adjacent structures, and endogenous spread through bloodstream sources[1,2]. Prompt clinical diagnosis and initiation of treatment are critical to preserve visual function, as the incidence of infectious endophthalmitis leading to no light perception vision in the affected eye ranges from 23% to 35%[3].

The clinical diagnosis of endophthalmitis incorporates microbiological techniques to determine the causative pathogen to optimize treatment strategy. However, traditional microbiological methods currently used are suboptimal. Intraocular fluids are typically sampled with needle aspiration upon presentation, but the aspiration of vitreous humor can sometimes fail (resulting in a “dry tap”). Cultures of intraocular samples frequently do not reveal any pathogen or can take multiple days to grow on various selective media. Gram stains of intraocular samples are negative in 50–60% of cases, while cultures from vitreous aspirates are negative in up to 55% of cases, and cultures from aqueous aspirates are negative in up to 60% of cases [4-7]. Reported rates for positive cultures that result from vitrectomy samples ranges widely, from 44.6 to 90% of cases, but this range is further complicated by the fact that broad-spectrum intravitreal antibiotics are commonly administered prior to vitrectomy and can prevent the successful identification of intraocular pathogens[4,6].

Techniques that utilize molecular genetics, such as polymerase chain reaction (PCR), sequencing, and microarrays, can identify organisms with accuracy. However, these methods are costly, labor-intensive, require numerous reagents, and are dependent upon the proper selection of complementary primers. Many PCR techniques are unable to provide any information on antimicrobial susceptibilities, and organisms that are difficult to isolate and grow, may require analysis in specialized centers [8]. The emergence of antimicrobial resistance also has serious implications on patient outcome from an epidemiological and public health perspective, and the accurate and the rapid identification of causative pathogens and the determination of their susceptibility profile can aid in the appropriate management of endophthalmitis[9-11].

Matrix Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS) is a promising analytical tool for the expedient identification of pathogens. In the face of increasing antibiotic resistance to empiric antibiotics, the accurate identification of pathogens is important to design targeted treatment and minimize the use of broad-spectrum antibiotics[9]. MALDI-TOF MS laser ionizes whole cell extracts from colonies grown in culture to produce a peptide fingerprint profile, and compares the profile against a proteomic database to identify a pathogen to a species level[3,12-14]. However, MALDI-TOF MS is currently used only in cases where there is already positive organism growth from cultures, and limited data exist for the direct analysis of patient samples[9,13-15].

VITEK 2 is a commercially available antimicrobial susceptibility test (AST) system that utilizes fluorescence-based technology to analyze Gram-positive and Gram-negative bacteria[16,17]. Like MALDI-TOF MS, VITEK 2 is used to analyze microorganisms that are grown in cultures, as opposed to direct analysis of samples, and the AST system is used to analyze isolates that have been already been successfully identified. VITEK 2 AST has shown to have a high degree of agreement with standard methods for determining the minimum inhibitory concentration (MIC) of antibiotics, with a gain-of-time of hours to days and improved reproducibility[16-18]. Additionally, VITEK 2 has been implemented with the use of positive cultures in reported cases of endophthalmitis to determine the AST of causative pathogens[19]. To our knowledge, no data currently exist about using VITEK-2 directly on experimental or patient samples without prior positive culture.

In this report, we investigate the ability of MALDI-TOF MS and VITEK 2 to analyze intraocular samples from in vitro models of endophthalmitis in order to rapidly identify and establish the antimicrobial susceptibility profile of the organism involved.

Deisgn and methods

This study was carried out in strict accordance with the recommendations of, and approved by, the Institutional Biosafety Committee of the University of Chicago (Protocol ID: IBC0610) and the Institutional Animal Care and Use Committee of the University of Chicago (Protocol ID: 72609).

Vitreous humor preparation

Freshly enucleated porcine eyes were obtained within 6 hours of enucleation, and the ocular surface was sterilized by soaking in 5% Betadine solution for 10 seconds and allowed to dry for at least 2 minutes. Vitreous humor (VH) was aspirated with an 18-gauge needle fitted onto a 10ml syringe using sterile technique, and typical volumes obtained were 1.5-2ml per eye. The VH was filtered through a sterile 0.22μm PES membrane (Whatman, Clifton, NJ) and pooled together. The pooled VH was subjected to a second filter sterilization, aliquoted into 1ml Eppendorf tubes, and stored at -80°C until use.

Bacterial stock (BS) preparation

Methicillin-resistant S. aureus strain USA300 was used in this in vitro model of endophthalmitis because Staphylococci are one of the common causative organisms in post-cataract endophthalmitis [4,9,20]. S. aureus was streaked onto tryptic soy agar (TSA) and agar plates were incubated for 12 hours. An isolated colony of S. aureus was picked to inoculate 1.5ml of VH and incubated with shaking at 37°C for 7 hours to produce bacterial stock (BS).

In vitro endophthalmitis model

The following in vitro endophthalmitis model was applied for MALDI-TOF MS analysis (Vitek MS, Version 3.0, bioMérieux), and VITEK 2 automated antimicrobial susceptibility test (AST) system (VITEK 2, Version 7.01, bioMérieux) at the clinical microbiology laboratory at The University of Chicago Medical Center. 60 μl BS were mixed into 540 μl VH to make serial dilution samples of 101 to 1010. A 30-μl aliquot from each dilution and a negative control of VH were plated on TSA plates for enumeration of bacteria (colony forming units, cfu) in the BS. Plates were incubated at 37°C for 12 hours. The remainder dilution samples (510 μl) were incubated at 37°C for 11 hours so that bacteria could grow in the vitreous humor, producing the in vitro model of infectious endophthalmitis.

Following incubation of the serial dilution samples, a 30-μl aliquot of each sample was plated on TSA plates and incubated at 37°C for 12 hours for post-incubation enumeration of bacteria (Tables 1 and 2). The remaining samples (480 μl) were centrifuged at 16,000 x g at room temperature for 20 min to collect bacterial cells in pellets. The supernatant was carefully discarded without disturbing the pellets. The bacterial cell pellets were white and opaque with mucoid consistency (Fig 1). This in vitro endophthalmitis model was duplicated for separate analysis with MALDI-TOF MS and VITEK 2.

Table 1

Results from direct MALDI-TOF MS analysis of in vitro endophthalmitis samples.

Concentrations of S. aureus in vitreous humor pre-and post-incubation, descriptions of pellets, and MALDI-TOF MS results with confidence values are depicted. Confidence value scores of ≥60% indicate species-level identification.

	Pre-incubation (cfu/μl)	Post-incubation (cfu/μl)	Pellet appearance	Spot	Identified organism	Confidence value
101 dilution	1.178x104	1.15x105	White, opaque	1A	S. aureus	99.9%
				1B	S. aureus	99.9%
102 dilution	1.178x103	7.335x105	White, opaque	2A	S. aureus	99.9%
				2B	S. aureus	99.9%
103dilution	1.178x102	1.033x105	White, opaque	3A	S. aureus	99.9%
				3B	S. aureus	99.9%
104 dilution	1.178x101	7.9789x104	White, opaque	4A	No identification	n/a
				4B	S. aureus	99.9%
105 dilution	1.178	5.4334x104	White, opaque	5A	S. aureus	99.9%
				5B	S. aureus	99.9%
106 dilution	1.178x10-1	2.6165x104	White, opaque	6A	S. aureus	99.9%
				6B	S. aureus	99.9%
107dilution	1.178x10-2	7.889x103	White, opaque	7A	No identification	n/a
				7B	S. aureus	96.1%
108 dilution	1.178x10-3	3.1665x102	No visible pellet	8A	No identification	n/a
				8B	No identification	n/a
109 dilution	1.178x10-4	n/a	No visible pellet	9A	No identification	n/a
				9B	No identification	n/a
1010 dilution	1.178x10-5	n/a	No visible pellet	10A	No identification	n/a
				10B	No identification	n/a
Negative control—matrix only					No identification	n/a
Negative control–vitreous only					No identification	n/a
Positive control—Enterobacter aerogenes					Enterobacter aerogenes	99.9%
Positive control—S. aureus					S. aureus	99.9%

MALDI-TOF MS = Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry; S. aureus = Staphylococcus aureus; n/a = not applicable.

Table 2

Results from direct automated AST of in vitro endophthalmitis samples with VITEK 2.

Concentrations of S. aureus in vitreous humor pre-and post-incubation, McFarland units, time needed for analysis, antimicrobial agents tested, minimum inhibitory concentration, and results from VITEK 2 analysis with % identity of results compared to AST profile of positive control are depicted. Positive control was a colony of S. aureus analyzed per standard protocol.

Sample		Positive control S. aureus		Pellet 1		Pellet 2		Pellet 3		Pellet 4
Pre-incubation (cfu/μl)				1.67x105cfu/ul		1.67x104 cfu/ul		1.67x103cfu/ul		1.67x102 cfu/ul
Post-incubation (cfu/μl)				2.43x105 cfu/ul		2.65x105 cfu/ul		1.13 x105 cfu/ul		5.33x105cfu/ul
McFarland units		0.56 McFarland		0.62 McFarland		0.57 McFarland		0.63 McFarland		0.59 McFarland
Time for analysis		8h		9.25h		8.75h		8.25h		8.75h
Antimicrobial agent (MIC)
Beta-lactamase		Positive		Positive		Positive		Positive		Positive
Cefoxitin screen		Positive		Positive		Positive		Positive		Positive
Oxacillin		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)
Cefazolin		Resistant		Resistant		Resistant		Resistant		Resistant
Gentamicin		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)
Ciprofloxacin		Intermediate (= 2 μg/mL)		Sensitive (= 1 μg/mL)*		Sensitive (= 1 μg/mL)*		Intermediate (= 2 μg/mL)		Sensitive (= 1 μg/mL)*
Levofloxacin		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)
Moxifloxacin		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)
Clindamycin (inducible resistance)		Negative		Negative		Negative		Negative		Negative
Erythromycin		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)
Clindamycin		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)
Quinupristin/dalfopristin		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)
Linezolid		Sensitive (= 2 μg/mL)		Sensitive (= 1 μg/mL)*		Sensitive (= 1 μg/mL)*		Sensitive (= 1 μg/mL)*		Sensitive (= 1 μg/mL)*
Vancomycin		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)
Tetracycline		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)
Tigecycline		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)
Nitrofurantoin		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)
Rifampicin		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)
Trimethoprim/sulfamethoxazole		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)
% Identity to Positive control				88.9%		88.9%		94.4%		88.9%
Sample		Positive control S. aureus		Pellet 5		Pellet 6		Pellet 7
Pre-incubation (cfu/μl)				1.67x101 cfu/ul		1.67 cfu/ul		1.67x10-1 cfu/ul
Post-incubation (cfu/μl)				4.98x105 cfu/ul		2.40 x105cfu/ul		7.00x104 cfu/ul
McFarland units		0.56 McFarland		0.47 McFarland		0.58 McFarland		0.52 McFarland
Time for analysis		8h		8.5h		8.25h		8.25h
Antimicrobial agent (MIC)
Beta-lactamase		Positive		Positive		Positive		Positive
Cefoxitin screen		Positive		Positive		Positive		Positive
Oxacillin		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)		Resistant (≥ 4 μg/mL)
Cefazolin		Resistant		Resistant		Resistant		Resistant
Gentamicin		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)
Ciprofloxacin		Intermediate (= 2 μg/mL)		Sensitive (= 1 μg/mL)*		Sensitive (= 1 μg/mL)*		Sensitive (= 1 μg/mL)*
Levofloxacin		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)		Sensitive (= 0.5 μg/mL)
Moxifloxacin		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)
Clindamycin (inducible resistance)		Negative		Negative		Negative		Negative
Erythromycin		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)		Resistant (≥ 8 μg/mL)
Clindamycin		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)
Quinupristin/dalfopristin		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)		Sensitive (≤ 0.25 μg/mL)
Linezolid		Sensitive (= 2 μg/mL)		Sensitive (= 2 μg/mL)		Sensitive (= 2 μg/mL)		Sensitive (= 1 μg/mL)*
Vancomycin		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)		Sensitive (= 1 μg/mL)
Tetracycline		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)		Sensitive (≤ 1 μg/mL)
Tigecycline		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)		Sensitive (≤ 0.12 μg/mL)
Nitrofurantoin		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)		Sensitive (≤ 16 μg/mL)
Rifampicin		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)		Sensitive (≤ 0.5 μg/mL)
Trimethoprim/sulfamethoxazole		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)		Sensitive (≤ 10μg/mL)
% Identity to Positive control				94.4%		94.4%		88.9%

Asterisks (*) indicate AST results that deviated from the AST results of the positive control. AST = antimicrobial susceptibility test; S. aureus = Staphylococcus aureus.

Fig 1

Bacterial pellets formed following centrifugation of vitreous humor samples from in vitro endophthalmitis.

Bacterial pellets (indicated by arrows) were white with mucoid consistency, and progressively became smaller with each subsequent dilution. Below are pellets formed after incubation of VH with 106 dilution of bacterial stock (left tube) and 107 dilution of bacterial stock (right tube). VH = vitreous humor.

MALDI-TOF MS analysis

Sterile inoculating loops were used to apply portions of the bacterial pellet onto a spot on the target plate (Fig 2). One bacterial pellet was applied to two spots. Following the in vitro endophthalmitis model, the VH that was inoculated with more dilute concentrations of BS (≤1.178x10-3 cfu/μl) did not produce visible bacterial pellets, and so 480 μl of the supernatant was aspirated from the top of the sample and the remaining 100 μl were mixed with pipetting. If there were no visible pellets to smear onto the target plate, 1μl of fluid was applied onto 2 spots. Positive controls of S. aureus and Enterobacter aurogenes, and negative controls of matrix solution (α-cyano-4-hydroxycinnamic acid) and sterile VH were applied to one spot each. Each spot was overlaid with 1μl of matrix per manufacturer’s protocol and allowed to dry sufficiently. The target plate was subsequently inserted into the MALDI-TOF MS machine.

Fig 2

Applying portions of pellets onto spots of the MALDI-TOF MS target plate with a sterile inoculating loop.

VITEK 2 analysis for AST

After bacterial pellets were produced with the in vitro endophthalmitis model, the pellets were resuspended in 2ml of 0.45% sterile saline to reach between 0.5 and 0.63 McFarland units per the manufacturer’s instructions. The VH that was inoculated with more dilute concentrations of VBS (≤1.67x10-2 cfu/μl) did not produce visible pellets and the minimum 0.5 McFarland units was not achievable for VITEK 2 analysis, and so those samples were excluded from analysis. Seven pellets were analyzed with VITEK 2. A colony of S. aureus grown on TSA agar was picked with a sterile inoculating loop and resuspended in 2ml of 0.45% sterile saline and analyzed as a positive control per standard protocol. The samples were identified as S. aureus in the program per manufacturer’s instructions and were loaded into the appropriate cartridge (VITEK 2 AST-GP67 cartridge, bioMérieux) (Fig 3). The susceptibilities to 18 antimicrobial agents were profiled with results of “Sensitive,” “Intermediate,” and “Resistant” (Table 2). Minimum inhibitory concentration (MIC) needed for each agent was also determined. Reactions to beta-lactamase agents and cefotoxin screen were determined as “Positive” or “Negative.”

Fig 3

Inserting AST GP67 cartridges (VITEK 2) into tubes containing pellets resuspended in 0.45% sterile saline.

Results

Pathogen identification from in vitro endophthalmitis sample by MALDI-TOF MS

The VH that were inoculated with at least 1.178x10-2 cfu/μl of bacteria produced visible pellets, corresponding to the VH inoculated with at least 107 dilution of the bacterial stock (Table 1). The pellets were white and opaque with mucoid consistency, and the size of the pellets gradually decreased with decreasing concentration of bacteria (Fig 1). The VH inoculated with bacterial stock dilutions of 108−1010 (≤1.178x10-3 cfu/μl) produced no visible pellets following centrifugation (Table 1).

Upon analysis by MALDI-TOF MS, all samples that produced visible pellets had positive identification of S. aureus with confidence values of ≥95%. The minimum concentration of bacteria in VH that resulted in a positive and accurate identification following incubation was 7.889x103 cfu/μl of VH, which had a confidence value of 96.1%. The samples that had lower concentrations of bacteria gave no identification from MALDI-TOF MS analysis.

One out of two spots from a pellet formed from VH with 7.98x104 cfu/μl (VH inoculated with 1.178x101 cfu/μl), and one spot from a pellet formed from VH with 7.89x103 cfu/μl (VH inoculated with 1.178x10-2 cfu/μl), gave no identification from analysis, likely due to inadequate application of the pellet onto the target plate. The other spots from each of the samples gave a single, positive identification of S. aureus. No other organisms were identified from the VH.

Positive controls of a colony of S. aureus and a colony of Enterobacter aerogenes were identified with 99.9% confidence value. Negative controls of matrix and uninoculated VH showed no identification of organisms, indicating there was no contamination of the experimental materials used.

The time for sample processing was 20 minutes. The time for applying a single spot on the target plate was 30 seconds. The time for analysis of a single spot on the target plate was less than 60 seconds by MALDI-TOF MS. The results were available less than 5 minutes following analysis. Overall, the time for pathogen identification with MALDI-TOF MS, from sample processing to the acquisition of results, was less than 30 minutes for a single sample.

Pathogen antimicrobial susceptibility by VITEK 2

The first seven pellets were analyzed with VITEK 2 because they reached adequate McFarland units for VITEK 2 analysis following resuspension in 0.45% sterile saline (Table 2).

Three samples (pellets 3, 5, 6) from the in vitro endophthalmitis model gave 17/18, or 94.4%, identity to the AST profile of the positive control of S. aureus. Pellets 5 and 6 showed sensitivity to ciprofloxacin at a MIC of 1 μg/mL, compared to the positive control’s intermediate reaction to ciprofloxacin at a MIC of 2 μg/mL. Pellet 3 showed sensitivity to linezolid at a MIC of 1 μg/mL, compared to the positive control’s sensitivity at a MIC of 2 μg/mL.

Four samples (pellets 1, 2, 4, 7) gave 16/18, or 88.9%, identity to the positive control S. aureus. All these pellets differed from the positive control AST profile in their sensitivity to ciprofloxacin at 1μg/mL compared to positive control’s intermediate reaction at a MIC of 2 μg/mL, and sensitivity to linezolid at 1 μg/mL compared to the positive control’s sensitivity at a MIC of 2 μg/mL.

One sample (pellet 5) was diluted to a McFarland of 0.47, less than the minimal threshold of 0.5 McFarland, but gave an AST profile with 94.44% identity to the positive control.

The range of time for antimicrobial susceptibility testing of the pellets was 8–9.25 hours, with an average of 8.5 hours.

Discussion

The role of MALDI-TOF MS and automated AST may mark a shift in microbiological methodology, at a time where the value of targeted therapy prevails in the face of increasing pathogen resistance and its consequent mortality and costs to healthcare.[9] Physicians treating patients with endophthalmitis must be aware of the potentially fatal consequences to vision, and the prognosis for patients can be very poor. In one study, 21.7% of eyes were reported of never being able to regain their baseline visual acuity after 6 months, and in another study up to 10% of eyes were reported to suffer from complete vision loss[1,21,22].

Using our in vitro endophthalmitis model, we demonstrate that the minimal processing (centrifugation of samples and washings with sterile water) of VH followed by direct analysis of the VH with MALDI-TOF MS without prior culture could lead to the identification of the pathogen with confidence values of up to 99.9% in most cases. A score of ≥60% indicates species-level identification[10-13]. We were also able to demonstrate that the minimum concentration of bacteria that led to identification of the pathogen was 7.889x106 cfu/μl. It has previously been established that positive identification of a microorganism requires at least 104 cells in a sample analyzed with MALDI-TOF MS[14]. We found that the time required, from sample processing to pathogen identification by MALDI-TOF MS, was less than 30 minutes for each sample. A previous study showed that the use of MALDI-TOF MS could decrease the time required for positive pathogen identification in human cases of endophthalmitis by up to 109 hours [23].

Compared to traditional identification methods, MALDI-TOF MS holds high potential as an analytical tool for the characterization of different types of microorganisms, and has a gain of time of days[13,15,23]. From the samples that formed pellets, only two out of the fourteen spots gave no identification likely due to inadequate application of the pellets onto the target plate. Every pellet analyzed gave a positive single identification of S. aureus. The samples that produced no visible pellets (VH inoculated with 108−1010 dilutions of S. aureus) gave no identification, likely due to insufficient number of microorganisms present in the sample for MALDI-TOF MS analysis.

We also demonstrated that an automated AST system, VITEK 2, can be used to directly analyze the VH of our in vitro model of endophthalmitis without prior culture and determine the AST of the pathogen with up to 94.44% accuracy compared to the positive control S. aureus. Our findings show that the growth of the causative pathogen through standard culturing methods is not necessary for analysis with VITEK 2, given that the minimum turbidity (0.5 McFarland units) of the analyzed material is met. The ability to directly determine the AST of a pathogen without growing the organism in culture, could significantly reduce the time and resources, and optimize the treatment strategy of patients with endophthalmitis. In our experiments, the range of time needed for the attainment of AST profiles with VITEK 2 was 8–9.25 hours, in contrast to the multiple days needed to successfully grow pathogens via culture with the current, conventional methodology of attaining AST results [20,23].

Although endophthalmitis is a rare condition, its incidence is likely to rise with the anticipated rise of ocular procedures. Cataract surgery and intravitreal injections are among the most commonly performed procedures in ophthalmology and medicine in general, and each procedure involves a risk for infection[9]. As the general population ages, the incidence of cataract surgeries is projected to increase dramatically in developed and developing countries, and the advent of new intravitreal agents for a broad array of retinal diseases, including neovascular age-related macular degeneration and diabetic macular edema, is likely to lead to an increase in intraocular injections performed on a daily basis[22,24-26]. Guidelines for preoperative preparation and sterile procedural techniques have likely aided in keeping reported rates of endophthalmitis low following cataract surgery (0.012 to 1.3%) and intravitreal injections (0.016 to 0.2%)[1]. However, the frequency with which these procedures are performed makes the risk of infectious complications a point of serious concern for patient care in ophthalmology.

During the time it takes to isolate an organism, the administration of broad-spectrum antibiotics typically is initiated to salvage the eye. Current recommendations for intravitreal antibiotics include vancomycin (1mg/0.1mL) and ceftazidime (2.25mg/0.1mL). However, broad-spectrum antibiotics can complicate the course of management because they can put the patient at future risk of succumbing to infection from an antimicrobial-resistant organism. Recent reports of endophthalmitis caused by vancomycin- and ceftazidime-resistant organisms underscore the importance of carefully considering the use of these agents for treatment[11,19,27,28]. Poor visual outcomes have especially been noted with Gram-negative organisms and certain Gram-positive organisms, especially those with resistance to broad spectrum antibiotics[9,19,29]. There is also a risk for retinal detachment from endophthalmitis, especially in cases of infection by more virulent pathogens and higher severity of disease at presentation[30,31]. The administration of antibiotics at the time of patient presentation may also prevent the identification of organisms through traditional microbiological methods.

Successful pathogen identification has been demonstrated with the direct application of cerebrospinal fluid and urine from cases of meningitis and urinary tract infections, respectively, onto MALDI-TOF MS without prior culture[14,32]. A case of pathogen identification through the direct application of MALDI-TOF MS on a vitreous sample from endophthalmitis, without prior culture, has recently been reported as well [33]. A wider breadth of organisms including other bacteria, mycobacteria, fungi, and polymicrobial infections could also be investigated with MALDI-TOF MS. Studies with in vivo animal models and human samples of endophthalmitis are needed to validate the clinical value of MALDI-TOF MS and automated AST in endophthalmitis. The potential effects of inflammatory responses on the specificity and sensitivity of direct analysis of samples with MALDI-TOF MS also require investigation.

There are limitations to the use of MALDI-TOF MS however, as the scope of pathogen identification is limited by the breadth of organisms established in the database of the specific biotyper software that is employed. For clinical applicability of the techniques we describe, there must be an adequate quantity of bacteria present in intraocular samples obtained from patients as well. Studies should also determine the ability of pathogen identification following antibiotic administration because unlike conventional microbiological methods, which require that the organism be intact or alive for proper identification, MALDI-TOF MS only requires the presence of particles of the culprit organism.

Directly applying endophthalmitis vitreous samples onto MALDI-TOF MS and VITEK 2 presents a promising new technique for the rapid identification of pathogens in the setting of endophthalmitis. Our findings demonstrate the proof-of-concept that the direct analysis of intraocular samples with these techniques could be used as an improved supplemental method to provide the rapid accuracy needed for proper treatment strategy in endophthalmitis. Further studies are needed to further validate potential clinical applications.

21 Oct 2019

PONE-D-19-26072

Rapid Pathogen Identification and Antimicrobial Susceptibility Testing in in vitro Endophthalmitis with Matrix Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry and VITEK 2 without Prior Culture

PLOS ONE

Dear Dr. Skondra,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This is an exciting new study and idea. both reviewers find it so as well. There are some minor issues that can easily be addressed and we would welcome the revised version.

We would appreciate receiving your revised manuscript by Dec 05 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Demetrios G. Vavvas

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for submitting your research work to PLOS One.

I find this article very interesting. Congratulations on the excellent work of the entire team and on the well-written manuscript. Despite its limitations, I agree that this technology can become a powerful tool for rapid identification of pathogens in patients with endophthalmitis.

There is a typo: p.6 the word Design (currently is DEISGN).

Thank you.

Reviewer #2: This is a very interesting study but would recommend the following modifications:

1. Please modify the last sentence of the first paragraph of Introduction, which states that 23-35% of eyes affected by endophthalmitis are left with no light perception. This very high rate of NLP visual outcome may be true for bleb-related endophthalmitis (the reference the authors give), but this is not true for other common types of endophthalmitis such as post-cataract endophthalmitis. Visual outcome is highly associated with pathogen; in coagulase-negative endophthalmitis - the major pathogen of post-cataract endophthalmitis -- NLP vision is very rare (<4%).

2. Please add a discussion of this study versus a similar one (not listed in Reference list) published in 2017 by Song Z, et al. "Using MALDI-TOF MS to test Staphylococcus aureus-infected vitreous". Mol Vis. 2017; 23: 407–415. The Song study used porcine eyes injected with S. aureus and directly tested the resulting infected vitreous with MALDI-TOF, so is similar in some regards to the present study -- results may in fact be complimentary. Also, the current study mentions a MALDI-TOF result in a patient with culture-negative endophthalmitis (ref 33), and the Song 2017 study mentions results from 2 patients with culture-positive endophthalmitis in which MALDI-TOF and standard culture yielded the same organism identification. This also may be worth noting.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

29 Nov 2019

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for submitting your research work to PLOS One.

I find this article very interesting. Congratulations on the excellent work of the entire team and on the well-written manuscript. Despite its limitations, I agree that this technology can become a powerful tool for rapid identification of pathogens in patients with endophthalmitis.

There is a typo: p.6 the word Design (currently is DEISGN).

Thank you; we have edited the typo.

Reviewer #2: This is a very interesting study but would recommend the following modifications:

1. Please modify the last sentence of the first paragraph of Introduction, which states that 23-35% of eyes affected by endophthalmitis are left with no light perception. This very high rate of NLP visual outcome may be true for bleb-related endophthalmitis (the reference the authors give), but this is not true for other common types of endophthalmitis such as post-cataract endophthalmitis. Visual outcome is highly associated with pathogen; in coagulase-negative endophthalmitis - the major pathogen of post-cataract endophthalmitis -- NLP vision is very rare (<4%).

Thank you; this sentence has been modified to state:

“Depending on the causative pathogen and pathophysiology, infectious endophthalmitis can lead to poor visual outcomes in the affected eye; for example, the incidence of no light perception ranges from 23% to 35% in bleb-related endophthalmitis(3,4).”

2. Please add a discussion of this study versus a similar one (not listed in Reference list) published in 2017 by Song Z, et al. "Using MALDI-TOF MS to test Staphylococcus aureus-infected vitreous". Mol Vis. 2017; 23: 407–415. The Song study used porcine eyes injected with S. aureus and directly tested the resulting infected vitreous with MALDI-TOF, so is similar in some regards to the present study -- results may in fact be complimentary. Also, the current study mentions a MALDI-TOF result in a patient with culture-negative endophthalmitis (ref 33), and the Song 2017 study mentions results from 2 patients with culture-positive endophthalmitis in which MALDI-TOF and standard culture yielded the same organism identification. This also may be worth noting.

The discussion has been modified to state:

“Another group previously reported on the implementation of MALDI-TOF MS in identifying a strain of S. aureus from in-vitro and ex-vivo models of endophthalmitis with porcine eyes, and in identifying the causative organisms in culture-positive human endophthalmitis samples, (34). However, we aimed to anticipate the extrapolation of our methods to potential clinical scenarios, and we thus optimized our methodology to require relatively minimal steps in sample preparation, clearly delineate the parameters and materials we employed, and help establish a range of minimum time needed for organism identification with MALDI-TOF MS.

Although the previously reported findings on the direct analysis of samples with MALDI-TOF MS support our study, a wider breadth of organisms including other bacteria, mycobacteria, fungi, and polymicrobial infections should also be investigated with MALDI-TOF MS.”

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Submitted filename: Response to Reviewers.docx

Click here for additional data file.

12 Dec 2019

Rapid Pathogen Identification and Antimicrobial Susceptibility Testing in in vitro Endophthalmitis with Matrix Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry and VITEK 2 without Prior Culture

PONE-D-19-26072R1

Dear Dr. Skondra,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

Demetrios G. Vavvas

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: I Don't Know

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

17 Dec 2019

PONE-D-19-26072R1

Rapid Pathogen Identification and Antimicrobial Susceptibility Testing in in vitro Endophthalmitis with Matrix Assisted Laser Desorption-Ionization Time-of-Flight Mass Spectrometry and VITEK 2 without Prior Culture

Dear Dr. Skondra:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Demetrios G. Vavvas

Academic Editor

PLOS ONE